Suven Life Sciences Reports Wider Q1 Net Loss Despite Revenue Growth Aug 13, 2025
Suven Life Sciences Initiates Phase 2B Trial for Novel Depression Treatment Jul 16, 2025
More news about Suven Life Sciences
03Jul 25
Suven Life Sciences Allocates 29.85 Lakh Convertible Warrants to Abakkus Fund
Suven Life Sciences has allocated 29.85 lakh convertible warrants to Abakkus Diversified Alpha Fund, managed by Sunil Singhania. This allocation could potentially lead to changes in shareholding structure, capital infusion, and future equity expansion for the pharmaceutical company.
13May 25
Suven Life Sciences Secures ₹857 Crore Through Preferential Issue, Backed by Market Veterans
Suven Life Sciences has approved a preferential issue of 6.4 crore convertible warrants at ₹134 per warrant, raising up to ₹857 crore. The issue attracted investments from funds managed by market veterans Sunil Singhania and Prashant Jain. The issue price represents a 12.40% discount to the previous closing price. Following the announcement, the company's shares jumped 11.80%, reflecting positive market sentiment.
13May 25
Suven Life Sciences Issues Convertible Warrants and Reports Q4 FY24 Financial Results
Suven Life Sciences has issued 62 lakh equity convertible warrants at Rs. 134 each to two investment funds. The company's Q4 FY24 results show a 59.70% decrease in revenue to ₹2.70 crore and an increased net loss of ₹43.90 crore. For the full FY24, revenue improved by 49.09% to ₹32.80 crore, but the company still reported a net loss of ₹105.10 crore.